Donepezil Viatris (Donepezil Hydrochloride)

Donepezil Viatris is indicated for the management of mild to moderate Alzheimer’s disease, where it may help improve cognition, behavior, and daily functioning, in patients diagnosed by a qualified clinician.

• Improves short-term memory and attention in some patients.
• May reduce caregiver-reported behavioral symptoms such as agitation.
• Supports activities of daily living by enhancing overall cognitive performance.
• Used as part of a comprehensive treatment plan that includes non‑pharmacologic interventions.
• May be considered when other cholinesterase inhibitors are not tolerated.

Side effects of Donepezil Viatris vary in frequency and severity; many patients experience mild symptoms, while serious reactions are less common.

Common

• Nausea, vomiting, or upset stomach, especially after first doses.
• Diarrhea or loose stools that may be intermittent.
• Insomnia, vivid dreams, or nighttime restlessness.
• Muscle cramps, weakness, or general fatigue.
• Decreased appetite leading to mild weight loss.

Serious

• Severe bradycardia, heart block, or other cardiac conduction abnormalities.
• Syncope (fainting) that may result in injury.
• Gastrointestinal bleeding or ulceration, especially with NSAIDs.
• Hepatotoxicity indicated by elevated liver enzymes or jaundice.
• Seizures or convulsions in susceptible individuals.

Precautions for Donepezil Viatris focus on patient history, comorbid conditions, and monitoring requirements to minimize risks.

• Assess cardiac history, especially bradyarrhythmias, before initiating therapy.
• Use caution in patients with asthma or chronic obstructive pulmonary disease.
• Monitor liver function tests periodically during long‑term treatment.
• Evaluate for gastrointestinal ulcers or bleeding risk, particularly if NSAIDs are co‑administered.
• Adjust dose or discontinue if severe nausea, vomiting, or weight loss occurs.
• Discuss potential pregnancy and lactation considerations with a healthcare professional.

Donepezil Viatris may interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Concurrent use with strong anticholinergic agents that may counteract its effect.
• Combination with other cholinesterase inhibitors, which can increase risk of toxicity.
• Use with medications known to prolong the QT interval in susceptible patients.

Use with caution

• Co‑administration with beta‑blockers or calcium channel blockers affecting heart rate.
• Concomitant use of NSAIDs or aspirin, which may raise gastrointestinal bleeding risk.
• Concurrent use of drugs metabolized by CYP2D6, such as certain antidepressants, may alter donepezil levels.